4/A: Frazier Life Sciences X, L.P. Corrects Ownership Reporting in HilleVax, Inc. (HLVX) Shares

Frazier Life Sciences X, L.P. files an amended Form 4 to correct an error in a previous filing regarding the purchase of HilleVax, Inc. (HLVX) common stock.

Summary

• Frazier Life Sciences X, L.P. filed an amended Form 4 with the SEC on May 31, 2024, to correct a previous error in reporting the purchase of HilleVax, Inc. (HLVX) common stock.
• The original Form 4, filed on April 8, 2024, inadvertently reported that Frazier Life Sciences X, L.P. directly purchased 8,850 shares of HLVX.
• The amendment clarifies that the stock purchase was made by other funds affiliated with Frazier Life Sciences X, L.P.
• As of April 8, 2024, Frazier Life Sciences X, L.P. directly owns 8,535,337 shares of HLVX common stock.
• FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P., and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P.
• James N. Topper and Patrick J. Heron, as managing members of FHMLS X, L.L.C., share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

Sentiment

Score: 6

Explanation: The document is a routine correction of a previous filing. It doesn't indicate any significant positive or negative developments for the company, but the correction itself is a positive sign of transparency.

Negatives

• The initial Form 4 filing contained an error regarding the purchase of HilleVax shares, requiring an amendment.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership of company stock by directors, officers, and principal stockholders, providing transparency to the market.

Stakeholder Impact

• The correction of the filing ensures accurate information is available to shareholders and the public.

Key Dates